Active ingredients:

500 mg, 1 g or 2 g Cefepime as Dihydrochloride Monohydrate.

CEBOPIM is a 4th generation broad-spectrum cephalosporin antibiotic that extended spectrum of activity against gram-positive and gram-negative bacteria. The mechanism of action of cefepime is based on inhibition of bacterial cell wall synthesis (in the growth phase). Cefepime has a low affinity for chromosomally-encoded beta-lactamases. Cefepime is highly resistant to hydrolysis by most beta-lactamases and exhibits rapid penetration into gram-negative bacterial cells. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins.

Indications

Adults Infections caused by microorganisms susceptible to CEBOPIM:

• respiratory infections, including pneumonia and bronchitis;
• skin and soft-tissue infections;
• intra-abdominal infections, including peritonitis and gallbladder infections;
• gynecological infections;
• septicemia;
• empirical treatment of patients with febrile neutropenia;
• prophylaxis in intra-abdominal surgery.

Children

• pneumonia;
• skin and soft-tissue tissue infections;
• septicemia;
• empirical treatment of patients with febrile neutropenia;
• bacterial meningitis.

CEBOPIM is also used for the prevention of post-operative infectious complications after abdominal surgery.

Dosage and pharmaceutical form:

powder for solution for injection 500 mg; 1 vial with powder; 1 vial with powder per package.

powder for solution for injection 1 g; 1 vial with powder; 1 vial with powder per package; 1 vial with powder together with solvent (water for injection) 5 ml or 10 ml in an ampoule in a pack with cardboard partition.

powder for solution for injection 2 g; 1 vial with powder; 1 vial with powder per package.